DULUTH, Ga., Jan. 9, 2020 /PRNewswire/ -- Sebacia, Inc.,
a privately held commercial stage dermatology and aesthetics
company, today provided a business update, first announcing an
update to its leadership team. Mr. Chuck
Abraham has been appointed Chief Executive Officer to lead
the Company's commercial strategy and execution, including the
planned U.S. commercial launch of Sebacia Microparticles in the US
for treatment of acne.
In addition, Sebacia announces the acquisition of all assets
related to Sienna Biopharmaceuticals' (NASDAQ: SNNA) SNA-001
(silver photoparticle technology) which is a late stage asset
pursuing an FDA clearance for light hair removal. This
includes all related intellectual property owned or licensed by
Sienna and the 510(k) application for light hair removal which was
submitted to FDA in September 2019.
The acquisition of these assets enables Sebacia to resolve the
outstanding patent interference litigation between The General
Hospital Corporation (GHC, the owner of certain patents licensed by
Sebacia) and Sienna Biopharmaceuticals.
Chuck Abraham, Chief Executive
Officer of Sebacia, said, "This acquisition enables Sebacia to
secure Sienna's silver photoparticle intellectual property,
effectively resolving all existing patent conflicts with Sienna,
while also establishing Sebacia as a leader in the use of
microparticles and laser energy in dermatology. Consolidating
the IP within Sebacia allows us to move forward and focus on making
our innovative gold microparticle treatment for acne available to
dermatologists and their patients and gives us an even deeper
pipeline of potential additional indications."
Mr. Abraham continued, "Separately, I'd like to thank The
Innovation Factory (TIF) and Anthony
Lando for their dedication and hard work leading the company
through incubation, R&D, and registration trials in both the EU
and U.S. I look forward to leading Sebacia through a successful
U.S. commercial launch."
In the U.S., Sebacia is preparing a targeted commercial launch
early in 2020 with plans to expand to additional territories later
in the year. Patients seeking treatment or physicians looking to
offer Sebacia Microparticles can find more information at
www.sebacia.com.
About Mr. Chuck
Abraham
Most recently Mr. Abraham was CEO of
OraMetrix, Inc. which developed 3-D technology solutions to improve
the quality and efficiency of orthodontic care. Mr. Abraham led
OraMetrix through the commercial launch of its cash pay service and
its successful acquisition by Dentsply Sirona in March 2018. Prior positions include leadership
roles with eMerge Interactive, Nellcor Puritan Bennett, and General
Electric Medical Systems. He attended Mississippi State University and received a
Bachelor of Science in Biological/Biosystems Engineering.
About Sebacia
Sebacia, Inc. is a private medical
device and aesthetics company focused on creating advanced
solutions for the treatment of dermatological conditions, with a
primary focus on a novel procedure-based acne treatment. Sebacia's
goal is to provide a better alternative to the daily use of topical
and systemic drugs currently available for the treatment of acne.
Sebacia's patented Microparticles were invented at Rice University, and the proprietary dermatology
applications were further developed by Sebacia in collaboration
with researchers from the Wellman Center of Photomedicine at
Massachusetts General Hospital. Sebacia Microparticles is cleared
for use in the U.S. and in the EU, the two largest dermatology
markets in the world. In the U.S. and Europe, Sebacia Microparticles is sold to
dermatologists in select markets. Investors in the company include
Accuitive Medical Ventures, Domain Associates, Partners Innovation
Fund, Salem Partners, and Versant Ventures.
Sebacia, Inc. is located in Atlanta,
Georgia. More information is available at www.sebacia.com or
follow us at www.twitter.com/SebaciaNews and
https://www.facebook.com/sebaciainc/.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/sebacia-announces-leadership-update-and-acquisition-of-silver-photoparticle-technology-assets-from-sienna-biopharmaceuticals-300984029.html
SOURCE Sebacia, Inc.
